Zemocimig

Multispecific antibody

Also known as RG6512, NXT007, RO7589655

Phase 1Mechanism not established
Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Other / comorbidity
NCT07416604 · Hoffmann-La Roche
2026-04-27 – 2032-01-29 · Hemophilia A
What this study did
NCT07838194 · Hoffmann-La Roche
2026-11-30 – 2031-09-30 · Hemophilia A
What this study did
NCT07416526 · Hoffmann-La Roche
2026-05-15 – 2031-09-23 · Hemophilia A
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT05987449 · Hoffmann-La Roche
2023-09-21 – 2033-12-11 · Hemophilia A
What this study did
Phase 1 (1)
Other / comorbidity
NCT06189508 · Hoffmann-La Roche
2024-02-14 – 2024-12-22 · Healthy Male Participants
What this study did

Competitive landscape

This drug's own stage for Hemophilia A and B: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Zemocimig: this drugStage not on recordMultispecific antibody—not yet gradedNo reviewed efficacy summary in this indication
Fitusiran (Qfitlia)ApprovedRNA / oligonucleotideAntithrombin (SERPINC1) mRNAPartial signal
NCT03417245: Estimated mean annualised bleeding rate: 3·1 fitusiran vs 31·0 on-demand factor (rate ratio 0·101; p<0·0001)
NCT03549871: Estimated mean ABR reduced by 79.7% (P = .0021) and 46.4% (P = .0598) vs BPA/CFC prophylaxis, respectively

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Zemocimig to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
Phase 3Hemophilia ARecruiting
Est. primary completion 2027-09-23 · NCT07416526 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
Phase 3Hemophilia ARecruiting
Est. primary completion 2028-02-29 · NCT07416604 · CT.gov ↗
What to watch
September 2028 (1)
Phase 3Hemophilia ARecruiting
Est. primary completion 2028-09-30 · NCT07838194 · CT.gov ↗
What to watch
2033 (1)
December 2033 (1)
Phase 1/2Hemophilia ARecruiting
Est. primary completion 2033-12-11 · NCT05987449 · CT.gov ↗
What to watch

See the full readout calendar ↗